NeuroMetrix (NASDAQ: NURO) and Asante Solutions (NASDAQ:PUMP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for NeuroMetrix and Asante Solutions, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroMetrix 0 0 2 0 3.00
Asante Solutions 1 1 10 1 2.85

NeuroMetrix presently has a consensus target price of $26.00, indicating a potential upside of 1,161.52%. Asante Solutions has a consensus target price of $18.70, indicating a potential upside of 64.18%. Given NeuroMetrix’s stronger consensus rating and higher possible upside, research analysts clearly believe NeuroMetrix is more favorable than Asante Solutions.

Institutional and Insider Ownership

6.5% of NeuroMetrix shares are held by institutional investors. 4.4% of NeuroMetrix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares NeuroMetrix and Asante Solutions’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NeuroMetrix -83.92% -209.56% -135.03%
Asante Solutions -2,766.48% N/A -208.12%

Valuation and Earnings

This table compares NeuroMetrix and Asante Solutions’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
NeuroMetrix $15.72 million 0.28 -$13.27 million ($20.01) -0.10
Asante Solutions $666.25 million 1.42 $51.36 million N/A N/A

Asante Solutions has higher revenue and earnings than NeuroMetrix.

NeuroMetrix Company Profile

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Asante Solutions Company Profile

Asante Solutions, Inc. is a medical device company. The Company is a manufacturer of Asante Snap Insulin Pump System (Snap system), which is a pump featuring a modular design with pre-filled insulin cartridges and disposable pump bodies, utilized in combination with a controller. The Snap system comprises four components: the Snap system controller, a disposable pump body, disposable pre-filled insulin cartridges and disposable infusion sets. The Snap system also incorporates a technology that allows for auto-priming, whereby, without user intervention, the infusion tubing is automatically filled with insulin every time a new cartridge is inserted. The disposable pump body, which contains a fresh battery, is designed to be used for a week. The Company markets the Snap system through distributors of medical equipment and supplies to individuals with diabetes.

Receive News & Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related companies with's FREE daily email newsletter.